Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,486 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00706576 | Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor | completed | Phase 1 | 14 | University of Missouri-ColumbiaOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT00920192 | Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer | completed | Phase 1 | 45 | GlaxoSmithKlineINDUSTRY | 3 | Jul 18, 2017 | clinicaltrials |
| NCT00861783 |
| Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma |
| completed |
| Phase 1 |
| 16 |
| Traws Pharma, Inc.INDUSTRY |
| 1 |
| Jun 23, 2017 |
| clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 4 | Mar 6, 2017 | clinicaltrials |
| NCT01656265 | Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 24 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01668134 | Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma | completed | Phase 1 | 28 | Washington University School of MedicineOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00516165 | RAD001 in Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01308723 | A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01897038 | A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00846131 | Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma | completed | Phase 1 | 24 | Northwestern UniversityOTHER | 1 | Sep 15, 2016 | clinicaltrials |
| NCT01733004 | A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Merrimack PharmaceuticalsINDUSTRY | 2 | Aug 4, 2016 | clinicaltrials |
| NCT01008566 | Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | May 12, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02724332 | Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | completed | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02210182 | A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma | completed | Phase 1 | 29 | Oncozyme Pharma Inc.INDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01147380 | Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation(MIAMINK) | completed | Phase 1 | 18 | Seigo NishidaOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02101593 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT01594125 | Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT02578602 | MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer | completed | Phase 1 | 26 | University of Southern CaliforniaOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00997022 | Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | completed | Phase 1 | 14 | Columbia UniversityOTHER | 1 | Aug 10, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01406574 | Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 23 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00493883 | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | completed | Phase 1 / Phase 2 | 81 | Southwestern Regional Medical CenterOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00844168 | Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant | completed | Phase 1 | 4 | University of WashingtonOTHER | 1 | Mar 27, 2015 | clinicaltrials |
| NCT00976170 | Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) | completed | Phase 1 | 42 | Chugai PharmaceuticalINDUSTRY | 2 | Oct 3, 2014 | clinicaltrials |
| NCT00978107 | Trial of TG4023 Combined With Flucytosine in Liver Tumors | completed | Phase 1 | 16 | TransgeneINDUSTRY | 1 | Jul 16, 2014 | clinicaltrials |
| NCT01540461 | Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) | completed | Phase 1 | 17 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT01116635 | Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 24 | University of British ColumbiaOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01129180 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 8 | Pierluigi PorcuOTHER | 1 | Dec 3, 2013 | clinicaltrials |
| NCT01129570 | Siliphos in Advanced Hepatocellular Carcinoma | completed | Phase 1 | 3 | Abby SiegelOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00956436 | Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 40 | BiogenINDUSTRY | 4 | Sep 16, 2013 | clinicaltrials |
| NCT01042041 | Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 26, 2013 | clinicaltrials |
| NCT01102400 | A Study of MEDI-575 in Patients With Advanced Solid Malignancies | completed | Phase 1 | 22 | AstraZenecaINDUSTRY | 1 | Feb 6, 2013 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00047346 | Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00844623 | TK-based Suicide Gene Therapy for Hepatocellular Carcinoma | completed | Phase 1 | 10 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT01040559 | Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas | completed | Phase 1 | 18 | Centre Hospitalier Universitaire DijonOTHER | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00712855 | A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma(HCC) | completed | Phase 1 | 23 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 1 | Oct 30, 2012 | clinicaltrials |
| NCT00614913 | Proton Beam Therapy for Treatment of Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 76 | Loma Linda UniversityOTHER | 1 | Aug 20, 2012 | clinicaltrials |
| NCT00802555 | Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 21 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Jul 12, 2012 | clinicaltrials |
| NCT00999882 | Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients | completed | Phase 1 | 26 | AstraZenecaINDUSTRY | 2 | Jul 10, 2012 | clinicaltrials |
| NCT00731445 | Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 43 | Zeria PharmaceuticalINDUSTRY | 1 | Jul 3, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Aug 2, 2017source: clinicaltrials